DNA Collection

Cheek swab performed in physician's office

Turn-around Time

7 to 10 days

Have a question?

References: 1. Weng L, Zhang L, Peng Y, Huang R. Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics. 2013;14(3):315-324. doi:10.2217/pgs.12.213. 2. Hertz D, McLeod H. Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology. Clin Cancer Res. 2014;20(10):2530-2540. doi:10.1158/1078-0432.ccr-13-2780. 3. U.S. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling.http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Updated May 20, 2015. Accessed March 18, 2016. 4. DPYD. PharmGKB website. https://www.pharmgkb.org/gene/PA145. Updated January 2016. Accessed March 18, 2016. 5. Lee A, Shi Q, Pavey E, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014;106(12):dju298. doi:10.1093/jnci/dju298. 6. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline information for mercaptopurine and TMPT. PharmGKB website. https://www.pharmgkb.org/guideline/PA166104945. Updated September 2015. Accessed March 18, 2016. 7. UGT1A1. PharmGKB website. https://www.pharmgkb.org/gene/PA420. Updated June 2015. Accessed March 18, 2016. 8. National Comprehensive Cancer Network. Colon cancer (version 2.2016). http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Updated November 2015. Accessed March 18, 2016. 9. Ichikawa W, Uehara K, Minamimura K, et al. An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients. Br J Cancer. 2015;112(10):1709-1716. doi:10.1038/bjc.2015.122. 10. CYP2C8. PharmGKB website. Available at: https://www.pharmgkb.org/gene/PA125. Accessed March 18, 2016. 11. MTHFR. PharmGKB website. Available at: https://www.pharmgkb.org/gene/PA245. Accessed March 18, 2016.